STOCK TITAN

DBV Technologies - DBVT STOCK NEWS

Welcome to our dedicated news page for DBV Technologies (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DBV Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DBV Technologies's position in the market.

Rhea-AI Summary
DBV Technologies has received feedback from the FDA regarding the design elements for the COMFORT safety studies. The protocol language for both studies will be simplified and harmonized. The COMFORT Toddlers study will have the same eligibility criteria as the Phase 3 efficacy study. DBV closed Q3 2023 with a cash balance of $149 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
DBV Technologies will report its third quarter 2023 financial results and provide a business update on October 31st. Interested participants can join the conference call or access the live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
Rhea-AI Summary
DBV Technologies to participate in H.C. Wainwright Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
conferences
-
Rhea-AI Summary
DBV Technologies receives feedback from FDA on design elements for Viaskin Peanut safety studies and reports Q2 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
DBV Technologies

Nasdaq:DBVT

DBVT Rankings

DBVT Stock Data

133.56M
43.83M
19.64%
0.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Montrouge

About DBVT

dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and